Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
✍ Scribed by Alexander M. Spence; Mitchel S. Berger; Robert B. Livingston; Francis Ali-Osman; Brian Griffin
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 347 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
✦ Synopsis
Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.